![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
Preview |
PDF (Data Supplement)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB |
| Item Type: | Article |
|---|---|
| Title: | TERT expression and clinical outcome in pulmonary carcinoids |
| Creators Name: | Werr, L., Bartenhagen, C., Rosswog, C., Cartolano, M., Voegele, C., Sexton-Oates, A., Di Genova, A., Ernst, A., Kahlert, Y., Hemstedt, N., Höppner, S., Mansuet Lupo, A., Pelosi, G., Brcic, L., Papotti, M., George, J., Bosco, G., Quaas, A., Tang, L.H., Robzyk, K., Kadota, K., Roh, M.S., Fanaroff, R.E., Falcon, C.J., Büttner, R., Lantuejoul, S., Rekhtman, N., Rudin, C.M., Travis, W.D., Alcala, N., Fernandez-Cuesta, L., Foll, M., Peifer, M., Thomas, R.K. and Fischer, M. |
| Abstract: | PURPOSE: The clinical course of pulmonary carcinoids ranges from indolent to fatal disease, suggesting that specific molecular alterations drive progression toward the fully malignant state. A similar spectrum of clinical phenotypes occurs in pediatric neuroblastoma, in which activation of telomerase reverse transcriptase (TERT) is decisive in determining the course of disease. We therefore investigated whether TERT expression defines the clinical fate of patients with pulmonary carcinoid. METHODS: TERT expression was examined by RNA sequencing in a test cohort and a validation cohort of pulmonary carcinoids (n = 88 and n = 105, respectively). A natural TERT expression cutoff was determined in the test cohort on the basis of the distribution of TERT expression, and its prognostic value was assessed by Kaplan-Meier survival estimates and multivariable analyses. Telomerase activity was validated by telomere repeat amplification protocol assay. RESULTS: Similar to neuroblastoma, TERT expression exhibited a bimodal distribution in pulmonary carcinoids, separating tumors into TERT-high and TERT-low subgroups. A natural TERT cutoff discriminated unfavorable from favorable clinical courses with high accuracy both in the test cohort (5-year overall survival [OS], 0.547 ± 0.132 v 1.0; P < .001) and the validation cohort (5-year OS, 0.788 ± 0.063 v 0.913 ± 0.048; P < .001). In line with these findings, telomerase activity was largely absent in TERT-low tumors, whereas it was readily detectable in TERT-high carcinoids. In multivariable analysis considering TERT expression, histology (typical v atypical carcinoid), and stage (≤IIA v ≥IIB), high TERT expression was an independent prognostic marker for poor survival, with a hazard ratio of 5.243 (95% CI, 1.943 to 14.148; P = .001). CONCLUSION: Our data demonstrate that high TERT expression defines clinically aggressive pulmonary carcinoids with fatal outcome, similar to neuroblastoma, indicating that activation of TERT may be a defining feature of lethal cancers. |
| Keywords: | Carcinoid Tumor, Kaplan-Meier Estimate, Lung Neoplasms, Prognosis, Telomerase, Tumor Biomarkers |
| Source: | Journal of Clinical Oncology |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Volume: | 43 |
| Number: | 2 |
| Page Range: | 214-225 |
| Date: | 10 January 2025 |
| Additional Information: | Janine Altmüller is a member of the Lung NEN Network. |
| Official Publication: | https://doi.org/10.1200/JCO.23.02708 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
